Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Inclusion Criteria:

• Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion Criteria:

• Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg